FibroGen
Dennis Kim currently serves as Associate Director of IT Operations at FibroGen, Inc. since February 2023, following a tenure as Sr. Manager of IT Operations. Prior to this role, Dennis held the position of IT Specialist - Cloud Infrastructure at Spectrum Pharmaceuticals, Inc. from June 2019 to February 2023. Dennis is an alumnus of the British Columbia Institute of Technology, having attended from 2008 to 2010.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.